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Zusammenfassung
Hintergrund: Die chemotherapeutische Behandlung von
chronisch dialysepflichtigen Patienten mit fortgeschritte-
nen oder metastasierten Tumoren ist häufig problema-
tisch, da für dieses spezielle Patientenkollektiv pharma-
kokinetische und pharmakodynamische Daten nur unzu-
reichend verfügbar sind. Kasuistik: Wir berichten im 
Folgenden über einen 45-jährigen dialysepflichtigen Pa-
tienten bei dem im Februar 2000 ein Kolonkarzinom im
Stadium 3 diagnostiziert wurde. Im Anschluss an die
operative Resektion wurde aufgrund der Dialysepflichtig-
keit eine dosisreduzierte, adjuvante Chemotherapie nach
dem sogenannten Mayo-Protokoll durchgeführt (i.v.
Bolus 5-Fluorouracil und Folinsäure). Aufgrund einer ex-
zessiven gastrointestinalen Toxizität musste diese Thera-
pie jedoch vorzeitig abgebrochen werden. Im April 2000
wurden dann Lebermetastasen diagnostiziert. Wir be-
gannen eine wöchentliche, dosisreduzierte Therapie mit
CPT-11 (50 mg/m2, 80 mg Gesamtdosis). Diese Therapie
wurde ohne wesentliche hämatologische oder nicht-hä-
matologische Toxizität (keine Toxizität Grad 3/4) toleriert.
Die Dosis wurde daraufhin auf 80 mg/m2 wöchentlich
(140 mg Gesamtdosis) gesteigert. Eine Dosiseskalation
auf 100 mg/m2 (180 mg Gesamtdosis) konnte wegen des
Auftretens einer schweren Diarrhö (Grad 4) nicht durch-
gehalten werden. Nach 2-monatiger Therapiedauer er-
reichte der Patient eine bis April 2001 anhaltende partiel-
le Remission (12 Monate). Seit Juli 2001 wird wegen
einer signifikanten Progression eine alternative Therapie
durchgeführt (HAI = intraarterielle, lokoregionäre Che-
motherapie). Schlussfolgerung: Diese Kasuistik zeigt die
Durchführbarkeit und Effektivität einer wöchentlichen,
dosisreduzierten Therapie mit CPT-11 bei einem dialyse-
pflichtigen Patienten mit metastasiertem Kolonkarzinom.
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Summary
Background: The cytotoxic treatment of patients suffer-
ing from advanced or metastatic cancer undergoing he-
modialysis due to chronic renal failure still remains a
problem, since for those patients pharmacokinetic and
pharmacodynamic data on most cytotoxic agents are
lacking. Case Report: We report a 45-year-old male who
suffered from chronic renal failure and was diagnosed
with stage-3 colorectal cancer (CRC) in February 2000.
After surgical removal of the tumor an adjuvant
chemotherapy of dose-reduced i.v. bolus 5-fluorouracil
and folinic acid was begun (Mayo protocol). Due to ex-
cessive gastrointestinal toxicity, therapy was discontin-
ued after the first cycle. In April 2000 liver metastases
were diagnosed. The patient was then put on a weekly
schedule of dose-reduced CPT-11 (50 mg/m2, 80 mg
total). No hematological or non-hematological toxicity
grade 3/4 was observed. Due to excellent tolerability and
lack of severe side effects the dose was increased up to
80 mg/m2 (140 mg total) weekly. A dose escalation to 100
mg/m2 (180 mg total) resulted in severe diarrhea (grade
4). Within 2 months of treatment the patient achieved a
lasting partial remission until April 2001 (12 months). A
significant progression of hepatic metastases required
an alternative treatment regimen beginning in July 2001
(HAI, hepatic artery infusion). Conclusion: This case re-
port demonstrates the feasibility and efficacy of a weekly
treatment with dose-reduced CPT-11 in a patient with
metastatic CRC on hemodialysis due to chronic renal fail-
ure.
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Introduction
Colorectal cancer (CRC) is one of the most prevalent malig-
nancies and second leading cause of cancer death in many in-
dustrialized countries [1–5]. 
Irinotecan (CPT-11) as a topoisomerase I inhibitor displays a
broad range of clinical activity against several tumors. The
drug lacks cross-resistance with 5-fluorouracil (5-FU) and is
commonly used for first- or second-line treatment of metasta-
tic CRC. As single agent therapy, CPT-11 can be administered
on weekly schedules (100–150 mg/m2, weekly × 4, q6w) as well
as on a 3-week schedule (250–350 mg/m2, q3w).
In the second-line treatment of metastatic CRC, CPT-11 in-
duces a response rate of 10–19% and increases significantly
the 1-year survival when compared to best supportive care
(36.2 vs. 13.8%) [1]. The main toxicity of single-agent CPT-11
therapy consists of diarrhea, cholinergic syndrome, alopecia,
nausea and vomiting, and neutropenia. 
As indicated in a pharmacokinetic study, nearly 80% of the
overall clearance of CPT-11 can be attributed to nonrenal
processes, including metabolic degradation of CPT-11. Part of
this nonrenal elimination was accounted for by fecal excretion
of unchanged CPT-11 and its four major metabolites.
In knowledge of these data, CPT-11 may be used in patients
suffering from chronic renal failure.
Case Report
We report a 45-year-old male who was started on hemodialysis in Sep-
tember 1994 due to chronic renal failure caused by rapid progressive
glomerulonephritis. In addition, he suffered from a congenital im-
munoglobulin deficiency syndrome with low levels of IgA and IgM, lead-
ing to frequent infections of the respiratory tract.
In February 2000 the patient was diagnosed with stage-3 CRC which was
surgically removed by left-sided hemicolectomy (pT3, pN2(9/15), M0, G2,
R0). Due to positive lymph node involvement, the patient was started on
an adjuvant chemotherapy schedule in March 2000, consisting of folinic
acid (FA) and dose-reduced 5-FU due to chronic renal failure (i.v. bolus
regimen ‘Mayo protocol’).
The first cycle consisted of FA (20 mg/m2) followed by 5-FU (200 mg/m2)
given as i.v. bolus on days 1–4. Even 2 days after finishing the first cycle,
the patient showed markedly gastrointestinal toxicity with excessive diar-
rhea and abdominal pain for a period of 10 days.
After reconstitution, the patient was diagnosed with elevated CEA levels
(6.6 ng/ml) in April 2000, leading to recurrence of CRC. A CT scan was
performed, detecting multiple hepatic metastases with a maximum exten-
sion of 2 cm.
At the end of April 2000 the patient then was started on a weekly sched-
ule of dose-reduced CPT-11 (50 mg/m2, 80 mg total). No hematological
and non-hematological toxicity grade 3/4 was observed and the patient
achieved a partial remission in the course of treatment, diagnosed by CT
scan and decreasing CEA levels (3.3 ng/ml). Due to excellent tolerability
with only mild diarrhea and lacking of severe side effects, the dose was es-
calated up to 80 mg/m2 (140 mg total dose) weekly. Side effects like severe
diarrhea (grade 4) occurred if the dose was escalated up to 100 mg/m2
(180 mg total dose), therefore treatment was continued with a weekly
dose of 80 mg/m2.
Although CEA levels had begun to increase since October 2000, imaging
procedures (CT scan) showed a stable disease without significant changes
in size of the hepatic metastases in January 2001. 
In April 2001, 12 months after starting CPT-11 treatment, a significant
progression of liver metastases was diagnosed by CT scan and required an
alternative treatment regimen (HAI, hepatic artery infusion) beginning in
July 2001 (fig. 1).
During the whole treatment period no significantly changes concerning
frequency of hemodialysis or laboratory tests of renal parameters were
observed.
Discussion
With an incidence of around 875,000 newly diagnosed cases
per year worldwide, CRC is one of the most frequent cancer
entities. Due to its frequency, it is not surprising when patients
suffering from chronic renal insufficiency are diagnosed with
CRC [3, 4].
The treatment of patients suffering from cancer undergoing
hemodialysis due to chronic renal failure still remains a prob-
lem, since for most cytotoxic agents pharmacokinetic and
pharmacodynamic data are lacking. 
Irinotecan [CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidi-
no]-carbonyloxycamptothecine] as a topoisomerase I inhibitor
has demonstrated clinical activity against 5-fluorouracil-re-
fractory CRC. As single-agent therapy, CPT-11 can be admin-
istered on a weekly schedule with doses between 100 and 150
mg/m2 (weekly), or on a 3-week schedule with doses between
250 and 350 mg/m2 (q3w) [4, 5].
In the second-line treatment of CRC, CPT-11 significantly in-
creases the 1-year survival compared to best supportive care
(36.2 vs. 13.8%) [1]. Also, when comparing CPT-11 treatment
to different 5-FU-based schedules, CPT-11 resulted in a sig-
nificant increased 1-year survival rate (44.8 vs. 32.4%, p =
0.0035) [2]. The response rates in the second-line treatment
ranged from 10 to 19%. A combination regimen of a protract-
ed 5-FU infusion with CPT-11 achieved a remission rate of
49% in the first-line therapy of CRC and the combination re-
sulted in a significantly increased survival rate [6, 7].
The main toxicity of single-agent CPT-11 therapy comprises
diarrhea, neutropenia, alopecia, cholinergic syndrome, and
nausea and vomiting [4, 5]. 
In a trial of Pitot et al. [8] of CPT-11 given on a weekly sched-
ule (n = 121; 90 patients pretreated with 5-FU, CPT-11 125 mg/
m2 weekly × 4, q6w), diarrhea grade 3/4 occurred in 36.4%,
and neutropenia grade 3/4 was observed in 21.5% of the pa-
tients (febrile neutropenia in 3.3%). The response rate in the
first-line treatment amounted to 25.8% (95% CI: 11.9–
44.6%), and to 13.3% (95% CI: 7.1–22.1%) in the second-line
treatment. In a trial of Rougier et al. [9] including 213 patients
treated on a 3-week schedule (350 mg/m2 q3w), grade-3/4 neu-
tropenia was observed in 47%, and diarrhea grade 3/4 occured
in 39% of the patients. An overall response rate of 18.8%
(95% CI: 8.9–32.6%) was observed in the first-line situation
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and amounted to 17.7% (95% CI: 11.5–25.3%) in the second-
line treatment.
When given CPT-11 (80 mg/m2 weekly) in combination with a
weekly 5-FU infusion schedule (up to 2.6 g/m2/24 h), neu-
tropenia did not exceed grade-2 toxicity, and diarrhea grade
3/4 only occurred when CPT-11 was escalated to a weekly
dose of 100 mg/m2. The response rate in this study amounted
to 64% (95% CI: 45–83%) [10].
In our patient the observation of grade-4 diarrhea over a peri-
od of more than a week after the first dose-reduced 5-FU/FA
cycle led to disruption of a 5-FU-based regimen. Although 5-
FU undergoes hepatic metabolization, it still remains unclear
whether the observed excessive gastrointestinal toxicity was
influenced by the chronic renal failure or whether it was a di-
hydropyrimidine dehydrogenase (DPD) deficiency.
The above-mentioned toxicity data of CPT-11 indicate that
single-agent CPT-11 at a weekly dose of 50 mg/m2, as adminis-
tered for the initial dose level in our patient, may result in a
treatment with low toxicity. In the course of treatment we
have not observed any toxicity which had exceeded grade 2,
although the dose was increased to 80 mg/m2 per week.
The reason for the low toxicity of the treatment may be
caused by metabolization of CPT-11. The drug was generated
into the active metabolite SN-38 (7-ethyl-1-hydroxycamp-
tothecine) by a carboxylesterase of the serum, liver, and the
small intestine [11]. Preliminary data suggested also an activa-
tion by carboxylesterase activity within the tumor [12]. As in-
dicated by a pharmacokinetic study of Sparreboom et al. [11],
nearly 80% of the overall clearance of CPT-11 can be attrib-
uted to nonrenal processes, including metabolic degradation
of CPT-11 by UDP glucuronosyltransferase 1A1 to an inac-
tive beta-glucuronide derivative (SN-38G). Part of this nonre-
nal elimination was accounted for by fecal excretion of un-
changed CPT-11 and its four major metabolites. The finding
that CPT-11 undergoes significant hepatic metabolization, and
the preliminary pharmacokinetic and toxicity results of a
study of CPT-11 administration in adults with liver dysfunc-
tion, suggested that the dose should be reduced by one third
in patients with total bilirubin more than 3× the upper limit of
the normal level [13].
Minor experiences are published for CPT-11 (and the camp-
tothecin analogue topotecan) in patients with renal dysfunc-
tion. For topotecan, one observed severe neutropenia in pa-
tients with moderate to severe renal dysfunction treated at
one third of the adult maximal tolerated dosage (0.5
mg/m2/day) [14].
Although renal excretion is a minor route of elimination for
CPT-11 and SN-38, no experiences concerning the administra-
tion of this cytotoxic agent in patients undergoing hemodialy-
sis are published so far. The lack of any severe toxicity in our
patient over a treatment period of 14 months leads to the con-
clusion that dose-reduced weekly CPT-11 may be feasible and
effective in patients undergoing hemodialysis due to chronic
renal failure.
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Fig. 1. Course of tre-
atment including CEA
levels and CT findings.
5-FU = 5-flourouracil;
FA = folinic acid;, 
HAI = hepatic artery
infusion; 
OP = surgical tumor
resection.
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